Krystal Biotech (KRYS)
(Delayed Data from NSDQ)
$156.88 USD
+1.20 (0.77%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $156.69 -0.19 (-0.12%) 7:58 PM ET
2-Buy of 5 2
D Value F Growth A Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$156.88 USD
+1.20 (0.77%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $156.69 -0.19 (-0.12%) 7:58 PM ET
2-Buy of 5 2
D Value F Growth A Momentum F VGM
Zacks News
Down -7.21% in 4 Weeks, Here's Why Krystal Biotech (KRYS) Looks Ripe for a Turnaround
by Zacks Equity Research
The heavy selling pressure might have exhausted for Krystal Biotech (KRYS) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Krystal Biotech (KRYS) is on the Move, Here's Why the Trend Could be Sustainable
by Zacks Equity Research
If you are looking for stocks that are well positioned to maintain their recent uptrend, Krystal Biotech (KRYS) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
Recent Price Trend in Krystal Biotech (KRYS) is Your Friend, Here's Why
by Zacks Equity Research
If you are looking for stocks that are well positioned to maintain their recent uptrend, Krystal Biotech (KRYS) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
Krystal Biotech, Inc. (KRYS) Is a Great Choice for 'Trend' Investors, Here's Why
by Zacks Equity Research
If you are looking for stocks that are well positioned to maintain their recent uptrend, Krystal Biotech, Inc. (KRYS) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
Can Krystal Biotech, Inc. (KRYS) Run Higher on Rising Earnings Estimates?
by Zacks Equity Research
Krystal Biotech, Inc. (KRYS) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
What Makes Krystal Biotech, Inc. (KRYS) a New Buy Stock
by Zacks Equity Research
Krystal Biotech, Inc. (KRYS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Krystal Biotech, Inc. (KRYS) is a Great Momentum Stock: Should You Buy?
by Zacks Equity Research
Does Krystal Biotech, Inc. (KRYS) have what it takes to be a top stock pick for momentum investors? Let's find out.
Here's Why Momentum in Krystal Biotech, Inc. (KRYS) Should Keep going
by Zacks Equity Research
Krystal Biotech, Inc. (KRYS) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Krystal Biotech, Inc. (KRYS) Tops Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Krystal Biotech, Inc. (KRYS) delivered earnings and revenue surprises of 157.69% and 119.92%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Krystal Biotech, Inc. (KRYS) Moves to Buy: Rationale Behind the Upgrade
by Zacks Equity Research
Krystal Biotech, Inc. (KRYS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Wall Street Analysts See a 42.55% Upside in Krystal Biotech, Inc. (KRYS): Can the Stock Really Move This High?
by Zacks Equity Research
The mean of analysts' price targets for Krystal Biotech, Inc. (KRYS) points to a 42.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Krystal (KRYS) Up 5% on Sale of FDA's Priority Review Voucher
by Zacks Equity Research
Krystal (KRYS) announces the sale of its priority review voucher for a consideration of $100 million. The stock of the company rises 5.2% on the news.
Krystal Biotech, Inc. (KRYS) is on the Move, Here's Why the Trend Could be Sustainable
by Zacks Equity Research
If you are looking for stocks that are well positioned to maintain their recent uptrend, Krystal Biotech, Inc. (KRYS) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
Krystal's (KRYS) Dermatology Drug Gets FDA Nod, Stock Up 10%
by Zacks Equity Research
Krystal's (KRYS) stock soars 10% on Friday after the company announces the FDA approval of Vyjuvek for the treatment of patients six months of age or older with dystrophic epidermolysis bullosa.
Krystal Biotech, Inc. (KRYS) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Krystal Biotech, Inc. (KRYS) delivered earnings and revenue surprises of -3.13% and 100%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Company News for Nov 30, 2021
by Zacks Equity Research
Companies in the news are: KRYS, ADGI, NRXP, HTZ
New Strong Sell Stocks for June 8th
by Zacks Equity Research
ASLN, CANG, ESLT, GCI, and KRYS have been added to the Zacks Rank #5 (Strong Sell) List on June 8, 2021.
New Strong Sell Stocks for May 28th
by Zacks Equity Research
ACET, FURY, KRYS, MRSN, and NBEV have been added to the Zacks Rank #5 (Strong Sell) List on May 28, 2021
New Strong Sell Stocks for May 21st
by Zacks Equity Research
ATHM, INVO, FOUR, KRYS, and RMAX have been added to the Zacks Rank #5 (Strong Sell) List on May 21, 2021
Krystal Biotech, Inc. (KRYS) is a Great Momentum Stock: Should You Buy?
by Zacks Equity Research
Does Krystal Biotech, Inc. (KRYS) have what it takes to be a top stock pick for momentum investors? Let's find out.
The Zacks Analyst Blog Highlights: ACADIA, Compugen, Cue Biopharma, Epizyme and Krystal Biotech
by Zacks Equity Research
The Zacks Analyst Blog Highlights: ACADIA, Compugen, Cue Biopharma, Epizyme and Krystal Biotech
5 Biotech Stocks Up More Than 100% This Year So Far
by Indrajit Bandyopadhyay
The biotech sector recovers on the back of rising M&A activities and pipeline successes in 2019 after a dismal 2018. Here we discuss five biotech companies recording impressive growth.
Krystal Biotech, Inc. (KRYS) Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Krystal Biotech, Inc. (KRYS).
Here's Why Krystal Biotech, Inc. (KRYS) is a Great Momentum Stock to Buy
by Zacks Equity Research
Does Krystal Biotech, Inc. (KRYS) have what it takes to be a top stock pick for momentum investors? Let's find out.
Krystal (KRYS) in Focus: Stock Moves 5.1% Higher
by Zacks Equity Research
Krystal (KRYS) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.